胰腺癌患者胰腺脂肪变性的高患病率：荟萃分析和系统回顾。

IF 2.8 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology Pub Date : 2025-02-01 DOI:10.1016/j.pan.2024.11.010

Cătălina Vlăduț , Corinna Steiner , Matthias Löhr , Dilara Turan Gökçe , Patrick Maisonneuve , Thomas Hank , Daniel Öhlund , Malin Sund , Sanne A. Hoogenboom

{"title":"胰腺癌患者胰腺脂肪变性的高患病率：荟萃分析和系统回顾。","authors":"Cătălina Vlăduț , Corinna Steiner , Matthias Löhr , Dilara Turan Gökçe , Patrick Maisonneuve , Thomas Hank , Daniel Öhlund , Malin Sund , Sanne A. Hoogenboom","doi":"10.1016/j.pan.2024.11.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>In the last decade there has been increasing interest in defining pancreatic steatosis (PS) and establishing its association with pancreatic ductal adenocarcinoma (PDAC). However, no consensus guidelines have yet been published on the management of PS. In this systematic review and meta-analysis performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we investigated the association between PS and PDAC.</div></div><div><h3>Design</h3><div>Medical literature between 2007 and 2023 was reviewed for eligible trials investigating the prevalence of PS in patients with PDAC. Eligible studies reporting on PS, assessed via imaging or histology, were included. The primary objective was to determine the association between PDAC and PS by comparing the prevalence of PS in individuals with- and without PDAC. Secondary, an evaluation was conducted to establish whether the method of assessment correlated with the association of PDAC and PS, and the prevalence of PDAC in individuals with PS. Measures of effect size were determined using odds ratios (ORs) and corresponding 95 % confidence intervals (95 % CI).</div></div><div><h3>Results</h3><div>The systematic review identified a total of 23 studies, of which seventeen studies examined PS prevalence among PDAC patients and were included in the meta-analysis. Overall, the pooled prevalence of PS in patients with PDAC was 53.6 % (95 % CI 40.9–66.2). No significant difference in PS prevalence was observed across various diagnostic methods or geographical regions. Overall, the pooled OR for PS in patients with PDAC compared to controls was 3.23 (95 % CI 1.86–5.60).</div></div><div><h3>Conclusions</h3><div>PDAC patients have a high prevalence of PS, and they are significantly more likely to have PS compared to controls. These findings emphasize the need to prioritize a standardized approach to the diagnosis, follow-up, and treatment of PS, with future studies focusing on identifying patients who would benefit from PDAC surveillance programs.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"25 1","pages":"Pages 98-107"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"High prevalence of pancreatic steatosis in pancreatic cancer patients: A meta-analysis and systematic review\",\"authors\":\"Cătălina Vlăduț , Corinna Steiner , Matthias Löhr , Dilara Turan Gökçe , Patrick Maisonneuve , Thomas Hank , Daniel Öhlund , Malin Sund , Sanne A. Hoogenboom\",\"doi\":\"10.1016/j.pan.2024.11.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>In the last decade there has been increasing interest in defining pancreatic steatosis (PS) and establishing its association with pancreatic ductal adenocarcinoma (PDAC). However, no consensus guidelines have yet been published on the management of PS. In this systematic review and meta-analysis performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we investigated the association between PS and PDAC.</div></div><div><h3>Design</h3><div>Medical literature between 2007 and 2023 was reviewed for eligible trials investigating the prevalence of PS in patients with PDAC. Eligible studies reporting on PS, assessed via imaging or histology, were included. The primary objective was to determine the association between PDAC and PS by comparing the prevalence of PS in individuals with- and without PDAC. Secondary, an evaluation was conducted to establish whether the method of assessment correlated with the association of PDAC and PS, and the prevalence of PDAC in individuals with PS. Measures of effect size were determined using odds ratios (ORs) and corresponding 95 % confidence intervals (95 % CI).</div></div><div><h3>Results</h3><div>The systematic review identified a total of 23 studies, of which seventeen studies examined PS prevalence among PDAC patients and were included in the meta-analysis. Overall, the pooled prevalence of PS in patients with PDAC was 53.6 % (95 % CI 40.9–66.2). No significant difference in PS prevalence was observed across various diagnostic methods or geographical regions. Overall, the pooled OR for PS in patients with PDAC compared to controls was 3.23 (95 % CI 1.86–5.60).</div></div><div><h3>Conclusions</h3><div>PDAC patients have a high prevalence of PS, and they are significantly more likely to have PS compared to controls. These findings emphasize the need to prioritize a standardized approach to the diagnosis, follow-up, and treatment of PS, with future studies focusing on identifying patients who would benefit from PDAC surveillance programs.</div></div>\",\"PeriodicalId\":19976,\"journal\":{\"name\":\"Pancreatology\",\"volume\":\"25 1\",\"pages\":\"Pages 98-107\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pancreatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1424390324007956\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1424390324007956","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：在过去的十年中，人们对胰腺脂肪变性（PS）的定义及其与胰腺导管腺癌（PDAC）的关系越来越感兴趣。然而，目前还没有关于PDAC管理的共识指南。根据系统评价和荟萃分析（PRISMA）指南的首选报告项目进行的系统评价和荟萃分析，我们调查了PS和PDAC之间的关系。设计：回顾2007年至2023年的医学文献，寻找PDAC患者中PS患病率的符合条件的试验。通过影像学或组织学评估，纳入了报道PS的符合条件的研究。主要目的是通过比较PDAC患者和非PDAC患者的PS患病率来确定PDAC与PS之间的关系。其次，进行了评估，以确定评估方法是否与PDAC和PS之间的关联以及PDAC在PS患者中的患病率相关。使用比值比（ORs）和相应的95%置信区间（95% CI）确定效应大小的测量。结果：系统评价共确定了23项研究，其中17项研究调查了PDAC患者中PS的患病率，并纳入了meta分析。总体而言，PDAC患者中PS的总患病率为53.6% （95% CI 40.9-66.2）。在不同的诊断方法或地理区域中，没有观察到PS患病率的显著差异。总体而言，PDAC患者与对照组相比，PS的总OR为3.23 （95% CI 1.86-5.60）。结论：PDAC患者有较高的PS患病率，与对照组相比，PDAC患者更容易发生PS。这些发现强调需要优先考虑一种标准化的方法来诊断、随访和治疗PS，未来的研究重点是确定哪些患者将从PDAC监测项目中受益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

High prevalence of pancreatic steatosis in pancreatic cancer patients: A meta-analysis and systematic review

Objective

In the last decade there has been increasing interest in defining pancreatic steatosis (PS) and establishing its association with pancreatic ductal adenocarcinoma (PDAC). However, no consensus guidelines have yet been published on the management of PS. In this systematic review and meta-analysis performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we investigated the association between PS and PDAC.

Design

Medical literature between 2007 and 2023 was reviewed for eligible trials investigating the prevalence of PS in patients with PDAC. Eligible studies reporting on PS, assessed via imaging or histology, were included. The primary objective was to determine the association between PDAC and PS by comparing the prevalence of PS in individuals with- and without PDAC. Secondary, an evaluation was conducted to establish whether the method of assessment correlated with the association of PDAC and PS, and the prevalence of PDAC in individuals with PS. Measures of effect size were determined using odds ratios (ORs) and corresponding 95 % confidence intervals (95 % CI).

Results

The systematic review identified a total of 23 studies, of which seventeen studies examined PS prevalence among PDAC patients and were included in the meta-analysis. Overall, the pooled prevalence of PS in patients with PDAC was 53.6 % (95 % CI 40.9–66.2). No significant difference in PS prevalence was observed across various diagnostic methods or geographical regions. Overall, the pooled OR for PS in patients with PDAC compared to controls was 3.23 (95 % CI 1.86–5.60).

Conclusions

PDAC patients have a high prevalence of PS, and they are significantly more likely to have PS compared to controls. These findings emphasize the need to prioritize a standardized approach to the diagnosis, follow-up, and treatment of PS, with future studies focusing on identifying patients who would benefit from PDAC surveillance programs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pancreatology 医学-胃肠肝病学

CiteScore

7.20

自引率

5.60%

发文量

194

审稿时长

44 days

期刊介绍： Pancreatology is the official journal of the International Association of Pancreatology (IAP), the European Pancreatic Club (EPC) and several national societies and study groups around the world. Dedicated to the understanding and treatment of exocrine as well as endocrine pancreatic disease, this multidisciplinary periodical publishes original basic, translational and clinical pancreatic research from a range of fields including gastroenterology, oncology, surgery, pharmacology, cellular and molecular biology as well as endocrinology, immunology and epidemiology. Readers can expect to gain new insights into pancreatic physiology and into the pathogenesis, diagnosis, therapeutic approaches and prognosis of pancreatic diseases. The journal features original articles, case reports, consensus guidelines and topical, cutting edge reviews, thus representing a source of valuable, novel information for clinical and basic researchers alike.